Details for Patent: 9,655,946
✉ Email this page to a colleague
Which drugs does patent 9,655,946 protect, and when does it expire?
Patent 9,655,946 protects DAPTOMYCIN and is included in one NDA.
This patent has twenty-four patent family members in nineteen countries.
Summary for Patent: 9,655,946
| Title: | Daptomycin formulations and uses thereof |
| Abstract: | Lyophilized daptomycin formulations having improved reconstitution times are provided. The lyophilized daptomycin formulations include an additive, which can be a pharmaceutically acceptable antioxidant, a pharmaceutically acceptable organic acid or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable glucose derivative or a pharmaceutically acceptable salt thereof, or a combination thereof. Also provided are methods of methods of preparing the lyophilized daptomycin formulations, and methods of treating bacterial infections and treating or preventing biofilms by using the lyophilized daptomycin formulations. |
| Inventor(s): | Alexiou; Jim (Oakleigh East, AU), Knill; Andrew (Bittern, AU), Norris; Noel (Endeavour Hills, AU), Whittaker; Darryl (Vermont, AU) |
| Assignee: | HOSPIRA AUSTRALIA PTY LTD. (Victoria, AU) |
| Application Number: | 14/427,618 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Compound; Process; Device; |
Drugs Protected by US Patent 9,655,946
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 210282-001 | Jun 21, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18 | ⤷ Try a Trial | |||
| Hospira | DAPTOMYCIN | daptomycin | POWDER;INTRAVENOUS | 210282-002 | Jun 21, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18 | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,655,946
| PCT Information | |||
| PCT Filed | September 11, 2013 | PCT Application Number: | PCT/IB2013/002191 |
| PCT Publication Date: | March 20, 2014 | PCT Publication Number: | WO2014/041425 |
International Family Members for US Patent 9,655,946
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013316779 | ⤷ Try a Trial | |||
| Australia | 2018217322 | ⤷ Try a Trial | |||
| Brazil | 112015005400 | ⤷ Try a Trial | |||
| Canada | 2884484 | ⤷ Try a Trial | |||
| Chile | 2015000608 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
